Back to Search
Start Over
Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.
- Source :
- BMC Pharmacology; 2012, Vol. 12 Issue 1, p8-15, 8p, 5 Diagrams, 1 Chart
- Publication Year :
- 2012
-
Abstract
- Background: Olanzapine is an atypical antipsychotic drug with high clinical efficacy, but which can cause severe weight gain and metabolic disorders in treated patients. Blockade of the histamine 1 (H<subscript>1</subscript>) receptors is believed to play a crucial role in olanzapine induced weight gain, whereas the therapeutic effects of this drug are mainly attributed to its favourable serotoninergic 2A and dopamine 2 (5HT<subscript>2A</subscript>/D<subscript>2</subscript>) receptor binding affinity ratios. Results: We have synthesized novel olanzapine analogues 8a and 8b together with the already known derivative 8c and we have examined their respective in vitro affinities for the 5HT<subscript>2A</subscript>, D<subscript>2</subscript>, and H<subscript>1</subscript> receptors. Conclusions: We suggest that thienobenzodiazepines 8b and 8c with lower binding affinity for the H<subscript>1</subscript> receptors, but similar 5HT<subscript>2A</subscript>/D<subscript>2</subscript> receptor binding affinity ratios to those of olanzapine. These compounds may offer a better pharmacological profile than olanzapine for treating patients with schizophrenia. [ABSTRACT FROM AUTHOR]
- Subjects :
- OLANZAPINE
ANTIPSYCHOTIC agents
METABOLIC disorders
HISTAMINE
DOPAMINE
Subjects
Details
- Language :
- English
- ISSN :
- 14712210
- Volume :
- 12
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- BMC Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 83359648
- Full Text :
- https://doi.org/10.1186/1471-2210-12-8